Article
Geriatrics & Gerontology
Xiaoling Zhong, Ashok Narasimhan, Libbie M. Silverman, Andrew R. Young, Safi Shahda, Sheng Liu, Jun Wan, Yunlong Liu, Leonidas G. Koniaris, Teresa A. Zimmers
Summary: Cachexia in patients with pancreatic ductal adenocarcinoma displays sex-specific phenotypes, with male patients experiencing earlier and more severe cachexia. The reproductive hormone and cytokine Activin plays a significant role in muscle wasting in male patients.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
(2022)
Review
Cell Biology
Pasquale Esposito, Daniela Verzola, Daniela Picciotto, Leda Cipriani, Francesca Viazzi, Giacomo Garibotto
Summary: The hypothesis suggests that myostatin and activin-A are involved in vascular damage in atherosclerosis and CKD, binding to different activin receptors and activating distinct signaling pathways. Myostatin promotes vascular inflammation and premature aging, while activin-A is implicated in vascular calcification and CKD-related mineral bone disorders. Understanding their roles in vascular disease and bone metabolism could lead to novel therapeutic opportunities.
Article
Oncology
Kako Hanada, Kunpei Fukasawa, Hiroki Hinata, Shu Imai, Kentaro Takayama, Hideyo Hirai, Rina Ohfusa, Yoshio Hayashi, Fumiko Itoh
Summary: Cancer cachexia is a disease that leads to continuous skeletal muscle wasting and is a major cause of cancer-related death. Researchers have identified a potential new therapeutic tool for suppressing muscle wasting in cancer cachexia, which involves the combined use of a myostatin inhibitor and a ghrelin receptor agonist. This combination treatment has been shown to effectively alleviate muscle wasting and improve survival in animal models.
Article
Geriatrics & Gerontology
Yi Luan, Yaqi Zhang, Seok-Yeong Yu, Mikyoung You, Pauline C. Xu, Soonkyu Chung, Takeshi Kurita, Jie Zhu, So-Youn Kim
Summary: Cancer-associated cachexia (CAC) is a complex syndrome that leads to progressive muscle wasting and adipose loss in cancer patients, resulting in increased morbidity and mortality risk. This study focuses on understanding the underlying mechanisms of CAC progression using a transgenic mouse model with ovarian tumors. The researchers found that the mouse model closely mimics the progression of CAC seen in humans, including severe body weight loss, muscle atrophy, and adipose tissue wasting. The study also identified potential biomarkers for CAC and revealed specific mechanisms involved in muscle and adipose tissue deterioration.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
(2022)
Article
Transplantation
Stanislas Bataille, Laetitia Dou, Marc Bartoli, Marion Sallee, Julien Aniort, Borhane Ferkak, Rania Chermiti, Nathalie McKay, Nathalie Da Silva, Stephane Burtey, Stephane Poitevin
Summary: In chronic kidney disease (CKD), the plasma concentrations of myostatin and activin A are increased, possibly due to reduced renal clearance. Furthermore, we observed increased production of activin A in the kidney and heart, which may be related to muscle wasting. Therefore, myostatin and activin A should be added to the list of uremic toxins.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2022)
Article
Chemistry, Organic
Hideyuki Okamoto, Atsuhiko Taniguchi, Shoya Usami, Masahiro Katsuyama, Sho Konno, Akihiro Taguchi, Kentaro Takayama, Yoshio Hayashi
Summary: The study synthesized myostatin-binding peptides with a photooxygenation catalyst, placed at different positions, successfully achieving selective photooxygenation of myostatin, effectively inhibiting its function, and exhibiting low phototoxicity.
ORGANIC & BIOMOLECULAR CHEMISTRY
(2021)
Article
Geriatrics & Gerontology
Kazuhiro Maeta, Manal Farea, Hisahide Nishio, Masafumi Matsuo
Summary: A novel splice variant of the human MSTN gene, myostatin-b, was identified in this study. Myostatin-b can inhibit myostatin signaling in a specific manner and enhance myoblast proliferation by regulating the cell cycle. This discovery suggests that myostatin-b could be developed as a natural myostatin inhibitor.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
(2023)
Article
Geriatrics & Gerontology
Hailun Xie, Guotian Ruan, Lishuang Wei, Heyang Zhang, Yizhong Ge, Qi Zhang, Shiqi Lin, Mengmeng Song, Xi Zhang, Xiaoyue Liu, Xiangrui Li, Kangping Zhang, Ming Yang, Meng Tang, Chun-Hua Song, Jialiang Gan, Han-Ping Shi
Summary: The hand grip strength-based cancer cachexia index (H-CXI) is a simple and practical predictor for cancer cachexia and prognosis in patients with cancer.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
(2023)
Article
Endocrinology & Metabolism
Catherine L. Omosule, Dominique Joseph, Brooke Weiler, Victoria L. Gremminger, Spencer Silvey, Youngjae Jeong, Ashique Rafique, Pamela Krueger, Sandra Kleiner, Charlotte L. Phillips
Summary: This study investigated the effects of inhibiting activin A, myostatin, or both on the musculoskeletal system in mice with osteogenesis imperfecta. The results showed that the combination of inhibiting activin A and myostatin was the most effective in increasing muscle mass and bone strength.
JOURNAL OF BONE AND MINERAL RESEARCH
(2022)
Review
Cell Biology
Juha J. Hulmi, Tuuli A. Nissinen, Fabio Penna, Andrea Bonetto
Summary: Muscle wasting, known as cachexia, is common in cancer patients and is associated with poor prognosis. Anticancer treatments may exacerbate cachexia. Preclinical studies have shown that blocking ACVR2 signaling can preserve muscle mass and improve survival, but further research is needed to determine if improved survival directly results from muscle preservation.
Article
Geriatrics & Gerontology
Se-Jin Lee, Shalender Bhasin, Lloyd Klickstein, Venkatesh Krishnan, Daniel Rooks
Summary: Considerable progress has been made in understanding the regulatory and signaling mechanisms of myostatin and other secreted proteins in controlling skeletal muscle mass. The development of biologics targeting this pathway has shown potential benefits in increasing muscle mass and function, and has been tested in clinical trials for various muscle and metabolic diseases. Myostatin inhibitors may offer potential therapeutic options for metabolic disorders by increasing muscle mass.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Yohan Han, Hyo In Kim, Jinbong Park
Summary: The lack of research evidence and trials on cancer-induced cachexia limits the therapeutic potential of natural products. This review summarizes single natural product extracts for cancer-induced cachexia and discusses their effects on cachexia induced by anticancer drugs. The inclusion of mice models encourages future research on cancer-induced cachexia.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Young Yun Jung, Jeong-Hyeon Ko, Jae-Young Um, Gautam Sethi, Kwang Seok Ahn
Summary: The study evaluated the potential effects of bergamottin on cancer-cachexia-induced muscle and fat loss, showing significant inhibitory effects on muscle and fat catabolism in both in vitro and in vivo conditions. The results suggest that bergamottin may have a potential impact on cancer cachexia, warranting further investigation in future clinical studies.
Review
Biochemistry & Molecular Biology
Aldona Kasprzak
Summary: Cancer cachexia is a multifactorial syndrome in patients with advanced cancer, particularly affecting colorectal cancer patients, with mechanisms driven by immune responses to the tumor. The tumor microenvironment plays a significant role in systemic inflammation and contributing to cachexia.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biochemistry & Molecular Biology
Jawed Akhtar Siddiqui, Ramesh Pothuraju, Parvez Khan, Gunjan Sharma, Sakthivel Muniyan, Parthasarathy Seshacharyulu, Maneesh Jain, Mohd Wasim Nasser, Surinder Kumar Batra
Summary: Growth differentiation factor 15 or macrophage inhibitory cytokine-1 (GDF15/MIC-1) is a divergent member of the transforming growth factor beta superfamily and has diverse pathophysiological roles in cancers, cardiometabolic disorders, and other diseases. Its role in cancer development and progression is complicated and depends on the specific cancer type and stage, and its mechanisms are related to its receptor GFRAL.
CYTOKINE & GROWTH FACTOR REVIEWS
(2022)